HK1052946A1 - Dry compositions containing hydrophobic amino acid - Google Patents

Dry compositions containing hydrophobic amino acid

Info

Publication number
HK1052946A1
HK1052946A1 HK03105181A HK03105181A HK1052946A1 HK 1052946 A1 HK1052946 A1 HK 1052946A1 HK 03105181 A HK03105181 A HK 03105181A HK 03105181 A HK03105181 A HK 03105181A HK 1052946 A1 HK1052946 A1 HK 1052946A1
Authority
HK
Hong Kong
Prior art keywords
amino acid
hydrophobic amino
saccharide
composition containing
dry composition
Prior art date
Application number
HK03105181A
Other languages
English (en)
Inventor
Chikamasa Yamashita
Masaaki Odomi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1052946A1 publication Critical patent/HK1052946A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
    • C09K15/16—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
HK03105181A 1999-12-24 2003-07-17 Dry compositions containing hydrophobic amino acid HK1052946A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP36805399 1999-12-24

Publications (1)

Publication Number Publication Date
HK1052946A1 true HK1052946A1 (en) 2003-10-03

Family

ID=18490866

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105181A HK1052946A1 (en) 1999-12-24 2003-07-17 Dry compositions containing hydrophobic amino acid

Country Status (13)

Country Link
US (1) US20030045481A1 (es)
EP (1) EP1254944B1 (es)
KR (1) KR100709792B1 (es)
CN (1) CN1253528C (es)
AT (1) ATE358171T1 (es)
AU (1) AU784885B2 (es)
CA (1) CA2395438C (es)
DE (1) DE60034149T2 (es)
DK (1) DK1254944T3 (es)
ES (1) ES2281370T3 (es)
HK (1) HK1052946A1 (es)
PT (1) PT1254944E (es)
WO (1) WO2001048117A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
US7023217B1 (en) 2004-12-16 2006-04-04 Honeywell International Inc. Method and apparatus for determining wear of resistive and conductive elements
WO2007013677A1 (ja) * 2005-07-27 2007-02-01 Ajinomoto Co., Inc. インターフェロン作用物質の活性増強剤
ES2387661B1 (es) * 2010-12-10 2013-10-31 Biolan Microbiosensores S.L. Proceso de purificación y estabilización de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); y uso de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3).

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
JPS58164683A (ja) * 1982-03-25 1983-09-29 Takeda Chem Ind Ltd 安定化された固体組成物
GB8703718D0 (en) * 1987-02-18 1987-03-25 Dalgety Uk Ltd Colour production
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5368879A (en) * 1993-07-23 1994-11-29 R. J. Reynolds Tobacco Company Flavorful dry food condiment and process of providing the same
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
JP4332694B2 (ja) * 1998-06-26 2009-09-16 大塚製薬株式会社 水溶性乾燥組成物
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤

Also Published As

Publication number Publication date
US20030045481A1 (en) 2003-03-06
DE60034149D1 (de) 2007-05-10
ATE358171T1 (de) 2007-04-15
CA2395438A1 (en) 2001-07-05
WO2001048117A1 (fr) 2001-07-05
KR20020070327A (ko) 2002-09-05
EP1254944A1 (en) 2002-11-06
EP1254944A4 (en) 2004-09-08
ES2281370T3 (es) 2007-10-01
AU2401501A (en) 2001-07-09
CN1253528C (zh) 2006-04-26
DK1254944T3 (da) 2007-07-02
CN1413241A (zh) 2003-04-23
CA2395438C (en) 2009-10-13
PT1254944E (pt) 2007-06-08
KR100709792B1 (ko) 2007-04-19
AU784885B2 (en) 2006-07-20
EP1254944B1 (en) 2007-03-28
DE60034149T2 (de) 2007-12-13

Similar Documents

Publication Publication Date Title
CA2400317A1 (en) Improved paste formulations
PT1123120E (pt) Formulacao medicinal em aerossol
BR0212876A (pt) Concentrado em suspensão, composição herbicida e métodos de aplicar uma composição herbicida e de preparar um concentrado em suspensão e uma composição herbicida
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DK1087960T3 (da) Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
WO2004026231A3 (en) Formulation for lipophilic agents
EP0391002A3 (en) Pharmaceutical compositions containing n-(3,4-dimethoxycinnamoyl) anthranilic acid
WO2007060104A3 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
WO1997030677A3 (en) Pentafluorobenzenesulfonamides and analogs
WO2007060108A3 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
DE69819871D1 (de) Stabile zusammensetzungen enthaltend ein retinoid und ein antioxidierendes system auf enzymbasis
ECSP045378A (es) Derivados novedosos de diazabiciclononeno
MY114944A (en) Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use
WO1998008517A3 (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
CA2316985A1 (en) Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
WO2001089520A3 (en) Dehydroascorbic acid formulations and uses thereof
EP0861663A3 (en) Osteoclastgenic inhibitory agent comprising interleukin-18
HK1052946A1 (en) Dry compositions containing hydrophobic amino acid
EP1136080A3 (en) Use of o-vanillin and o-vanillin/trolox combinations
AU2001289714A1 (en) Benzofuran derivatives and their use as antibacterial agents
UY27373A1 (es) Formulaciones de interferón beta-humano
HUP0202744A2 (hu) Orális, rivasztigmint tartalmazó szabályozott hatóanyag-leadású készítmények

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151222